作者
Thomas GP Grünewald, Marta Alonso, Sofia Avnet, Ana Banito, Stefan Burdach, Florencia Cidre‐Aranaz, Gemma Di Pompo, Martin Distel, Heathcliff Dorado‐Garcia, Javier Garcia‐Castro, Laura González‐González, Agamemnon E Grigoriadis, Merve Kasan, Christian Koelsche, Manuela Krumbholz, Fernando Lecanda, Silvia Lemma, Dario L Longo, Claudia Madrigal‐Esquivel, Álvaro Morales‐Molina, Julian Musa, Shunya Ohmura, Benjamin Ory, Miguel Pereira‐Silva, Francesca Perut, Rene Rodriguez, Carolin Seeling, Nada Al Shaaili, Shabnam Shaabani, Kristina Shiavone, Snehadri Sinha, Eleni M Tomazou, Marcel Trautmann, Maria Vela, Yvonne MH Versleijen‐Jonkers, Julia Visgauss, Marta Zalacain, Sebastian J Schober, Andrej Lissat, William R English, Nicola Baldini, Dominique Heymann
发表日期
2020/11/6
来源
EMBO molecular medicine
卷号
12
期号
11
页码范围
e11131
简介
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult‐to‐treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel …
学术搜索中的文章
TGP Grünewald, M Alonso, S Avnet, A Banito… - EMBO molecular medicine, 2020